capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
pharma · Non-Muscle Invasive Bladder Urothelial Carcinoma · Nasopharyngeal Cancinoma (NPC)
Chongqing Daxin Pharmaceutical
Chongqing Claruvis Pharmaceutical Co.,
Chongqing Daxin Pharmaceutical drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Chongqing, CN HQ
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Chongqing, CN
- Employees
- 5
- Programs
- 2
- Drugs
- 6
- Patents
- 0
Chongqing Daxin Pharmaceutical pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chongqing Daxin Pharmaceutical drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Chongqing Daxin Pharmaceutical in public FDA and regional records.
-
Development asset linked to Chongqing Daxin Pharmaceutical in public FDA and regional records.
-
Development asset linked to Chongqing Daxin Pharmaceutical in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Chongqing Daxin Pharmaceutical in public FDA and regional records.
-
Development asset linked to Chongqing Daxin Pharmaceutical in public FDA and regional records.